Product
Supplier
Encyclopedia
Inquiry
Home > News > Market Flash > Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown

Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown

ECHEMI 2025-12-12

The global obesity drug race has entered a new competitive phase as Wegovy’s momentum softens following multiple price reductions, while Mounjaro continues to dominate prescription rankings. Novo Nordisk has cut pricing in multiple markets to defend volume growth, but sales data indicate that tirzepatide’s superior clinical performance continues to anchor Lilly’s leadership. Despite Wegovy’s strong brand recognition, payer restrictions and affordability remain structural hurdles, especially as insurers intensify cost-containment efforts. The divergence underscores that efficacy, not price alone, is still the ultimate arbiter in the weight-loss drug hierarchy.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.